Staxyn generic
Staxyn is an orally disintegrating tablet owned by Bayer Hlthcare. The drug, which contains vardenafil hydrochloride as its active ingredient, was first authorized for market use on 17th June 2010. Staxyn holds 1 patent in total, none of which have expired as of now.
When will Staxyn generic be available?
The generic version of Staxyn can potentially be released after 23rd December 2028. This is the expiry date of the last patent (US8613950) held by Bayer Hlthcare for this drug. Following the end of this patent, it’s possible for other manufacturers to produce their own generic versions of Staxyn under a different brand name.
Staxyn uses
Staxyn is primarily used for treating erectile dysfunction. The drug works by increasing blood flow to the penis, which helps a man get and keep an erection. The active ingredient, vardenafil hydrochloride, is a phosphodiesterase type 5 (PDE5) inhibitor which contributes to the drug's effectiveness.
Staxyn patent expiration
Staxyn holds a total of 1 patent, with none having expired thus far. The last patent for Staxyn, titled 'Pharmaceutical forms with improved pharmacokinetic properties,' is set to expire on 23rd December 2028. This will be the potential date for the release of Staxyn generics. Below are the details of the patent: